Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Profit After Tax: 2012-2024

Historic Profit After Tax for Coherus Oncology (CHRS) over the last 13 years, with Dec 2024 value amounting to $28.5 million.

  • Coherus Oncology's Profit After Tax rose 6.47% to -$44.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $394.5 million, marking a year-over-year increase of 597.92%. This contributed to the annual value of $28.5 million for FY2024, which is 111.98% up from last year.
  • As of FY2024, Coherus Oncology's Profit After Tax stood at $28.5 million, which was up 111.98% from -$237.9 million recorded in FY2023.
  • Coherus Oncology's Profit After Tax's 5-year high stood at $132.2 million during FY2020, with a 5-year trough of -$291.8 million in FY2022.
  • Over the past 3 years, Coherus Oncology's median Profit After Tax value was -$237.9 million (recorded in 2023), while the average stood at -$167.0 million.
  • As far as peak fluctuations go, Coherus Oncology's Profit After Tax slumped by 317.10% in 2021, and later skyrocketed by 111.98% in 2024.
  • Coherus Oncology's Profit After Tax (Yearly) stood at $132.2 million in 2020, then crashed by 317.10% to -$287.1 million in 2021, then dropped by 1.62% to -$291.8 million in 2022, then rose by 18.46% to -$237.9 million in 2023, then skyrocketed by 111.98% to $28.5 million in 2024.